VTYX — Ventyx Biosciences Share Price
0.000.00%
Last trade - 00:00- $103.18m
- -$114.14m
- 32
- 50
- 43
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.41 | ||
| Price to Tang. Book | 0.41 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -56.28% | ||
| Return on Equity | -54.27% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 15.29 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 21st, 2018
- Public Since
- October 21st, 2021
- No. of Shareholders
- 12
- No. of Employees
- 79
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 71,161,201
- Address
- 12790 El Camino Real, Suite 200, SAN DIEGO, 92130
- Web
- https://ventyxbio.com/
- Phone
- +1 8589452393
- Auditors
- Ernst & Young LLP
Upcoming Events for VTYX
Ventyx Biosciences Inc Annual Shareholders Meeting
Similar to VTYX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Ventyx Biosciences share price?
As of Today at 23:57 UTC, shares in Ventyx Biosciences are trading at $1.45. This share price information is delayed by 15 minutes.
How has the Ventyx Biosciences share price performed this year?
Shares in Ventyx Biosciences last closed at $1.45 and the price had moved by -70.47% over the past 365 days. In terms of relative price strength the Ventyx Biosciences share price has underperformed the S&P500 Index by -73.37% over the past year.
What are the analyst and broker recommendations for Ventyx Biosciences?
The overall consensus recommendation for Ventyx Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ventyx Biosciences dividend yield?
Ventyx Biosciences does not currently pay a dividend.
Does Ventyx Biosciences pay a dividend?
Ventyx Biosciences does not currently pay a dividend.
When does Ventyx Biosciences next pay dividends?
Ventyx Biosciences does not currently pay a dividend.
How do I buy Ventyx Biosciences shares?
To buy shares in Ventyx Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ventyx Biosciences?
As of the previous close price of $1.45, shares in Ventyx Biosciences had a market capitalisation of $103.18m.
Where are Ventyx Biosciences shares listed?
Here are the trading details for Ventyx Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: VTYX
What kind of share is Ventyx Biosciences?
Based on an overall assessment of its quality, value and momentum Ventyx Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ventyx Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Ventyx Biosciences is $11.40. That is 686.21% above the last closing price of $1.45.
Analysts covering Ventyx Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$2.06 for the next financial year.
Find out moreWhat is the trend in the Ventyx Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ventyx Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -32.25%.
As of the last closing price of $1.45, shares in Ventyx Biosciences were trading -26.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ventyx Biosciences PE Ratio?
The Ventyx Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ventyx Biosciences?
Ventyx Biosciences' management team is headed by:
- Raju Mohan - CEO
- John Nuss - CSO
- Kathy Ogilvie - VOP
- Richard Gregg - EXO
- Chris Krueger - EXO